• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美国国立卫生研究院资助的HIV疫苗试验网络的研究生产力与合作:一项文献计量分析。

Research productivity and collaboration of the NIH-funded HIV vaccine trials network: A bibliometric analysis.

作者信息

Nye Jonathan, D'Souza M Patricia, Hu Dale, Ghosh Dolan

机构信息

NIAID, MSC 9808, Building 5601, 5601 Fishers Lane, Rockville, Maryland, 20852, USA.

Division of AIDS, NIAID, NIH, Bethesda, Maryland, USA.

出版信息

Heliyon. 2021 Jan 22;7(1):e06005. doi: 10.1016/j.heliyon.2021.e06005. eCollection 2021 Jan.

DOI:10.1016/j.heliyon.2021.e06005
PMID:33532641
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7829147/
Abstract

The HIV Vaccine Trials Network (HVTN) is the world's largest publicly funded, multi-disciplinary international collaboration facilitating the development of vaccines to prevent HIV/AIDS and has conducted the vast majority of HIV/AIDS clinical trials since its inception in 1999. Although scientific findings from the program have been published in scholarly journals, the impact of a large scientific research network such as the HVTN on the HIV/AIDS vaccine field has not been assessed. This paper describes and elucidates the productivity, influence, and collaboration among HVTN researchers over the last two decades. Our analyses indicate that the HVTN has funded a large number of HIV/AIDS vaccine safety and efficacy clinical trials through a strong global network of clinical sites. In addition, several metrics indicate HVTN researchers also published original research articles that are influential in the HIV vaccine field. Scientific research collaboration is critically important in a complex and multidisciplinary field such as HIV vaccine development as it allows improved sharing of knowledge and expertise as well as the pooling of resources and data. We found that collaboration in the HIV vaccine field increased during this time period and collaboration among HVTN authors increased even more. Combining these productivity, influence, and collaboration metrics with research outcomes can provide a comprehensive assessment of large complex programs such as the HVTN.

摘要

艾滋病疫苗试验网络(HVTN)是全球最大的由公共资金资助的多学科国际合作项目,致力于推动预防艾滋病病毒/艾滋病疫苗的研发。自1999年成立以来,该网络开展了绝大多数艾滋病病毒/艾滋病临床试验。尽管该项目的科学研究成果已在学术期刊上发表,但像HVTN这样的大型科研网络对艾滋病病毒/艾滋病疫苗领域的影响尚未得到评估。本文描述并阐明了HVTN研究人员在过去二十年中的生产力、影响力及合作情况。我们的分析表明,HVTN通过强大的全球临床站点网络资助了大量艾滋病病毒/艾滋病疫苗安全性和有效性临床试验。此外,多项指标显示,HVTN研究人员还发表了在艾滋病疫苗领域具有影响力的原创研究文章。在艾滋病疫苗研发这样复杂的多学科领域,科研合作至关重要,因为它能促进知识和专业技能的更好共享,以及资源和数据的汇集。我们发现,在此期间,艾滋病疫苗领域的合作有所增加,HVTN作者之间的合作增加得更多。将这些生产力、影响力和合作指标与研究成果相结合,可以对像HVTN这样的大型复杂项目进行全面评估。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f90d/7829147/3e5f5fd3ffa8/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f90d/7829147/0f543d28b4f1/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f90d/7829147/6059ee955b16/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f90d/7829147/ab74cc7e05c9/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f90d/7829147/3e5f5fd3ffa8/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f90d/7829147/0f543d28b4f1/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f90d/7829147/6059ee955b16/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f90d/7829147/ab74cc7e05c9/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f90d/7829147/3e5f5fd3ffa8/gr4.jpg

相似文献

1
Research productivity and collaboration of the NIH-funded HIV vaccine trials network: A bibliometric analysis.美国国立卫生研究院资助的HIV疫苗试验网络的研究生产力与合作:一项文献计量分析。
Heliyon. 2021 Jan 22;7(1):e06005. doi: 10.1016/j.heliyon.2021.e06005. eCollection 2021 Jan.
2
HIV Vaccine Trials Network: activities and achievements of the first decade and beyond.HIV疫苗试验网络:首个十年及之后的活动与成就
Clin Investig (Lond). 2012 Mar;2(3):245-254. doi: 10.4155/cli.12.8.
3
Behavioral risk assessment in HIV Vaccine Trials Network (HVTN) clinical trials: a qualitative study exploring HVTN staff perspectives.HIV 疫苗试验网络(HVTN)临床试验中的行为风险评估:一项探索 HVTN 工作人员观点的定性研究。
Vaccine. 2013 Sep 13;31(40):4398-405. doi: 10.1016/j.vaccine.2013.07.003. Epub 2013 Jul 13.
4
HIV-1 genetic diversity a challenge for AIDS vaccine development: a retrospective bibliometric analysis.艾滋病毒-1 遗传多样性对艾滋病疫苗开发的挑战:回顾性文献计量分析。
Hum Vaccin Immunother. 2022 Dec 31;18(1):2014733. doi: 10.1080/21645515.2021.2014733. Epub 2022 Jan 11.
5
Future paths for HIV vaccine research: Exploiting results from recent clinical trials and current scientific advances.HIV疫苗研究的未来路径:利用近期临床试验结果和当前科学进展
Curr Opin Mol Ther. 2010 Feb;12(1):39-46.
6
HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen.HIV gp120疫苗 - 瓦克斯根公司:AIDSVAX、AIDSVAX B/B、AIDSVAX B/E、HIV gp120疫苗 - 基因泰克公司、HIV gp120疫苗AIDSVAX - 瓦克斯根公司、HIV疫苗AIDSVAX - 瓦克斯根公司
Drugs R D. 2003;4(4):249-53. doi: 10.2165/00126839-200304040-00007.
7
Use of Bibliometric Analysis to Assess the Scientific Productivity and Impact of the Global Emerging Infections Surveillance and Response System Program, 2006-2012.运用文献计量分析评估全球新发传染病监测与应对系统项目(2006 - 2012年)的科研生产力与影响力
Mil Med. 2017 May;182(5):e1749-e1756. doi: 10.7205/MILMED-D-16-00276.
8
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.C 亚型 ALVAC-HIV 和双价 C 亚型 gp120/MF59 HIV-1 疫苗在南非低危、未感染 HIV 的成年人中的 1/2 期临床试验
Lancet HIV. 2018 Jul;5(7):e366-e378. doi: 10.1016/S2352-3018(18)30071-7. Epub 2018 Jun 18.
9
Evolution of global scientific collaboration in mRNA vaccine research: Insights from bibliometric and social network analysis (2010~2023).mRNA 疫苗研究的全球科学合作演变:文献计量学和社会网络分析的见解(2010~2023 年)。
Hum Vaccin Immunother. 2023 Dec 15;19(3):2276624. doi: 10.1080/21645515.2023.2276624. Epub 2023 Nov 14.
10
Substance use patterns of HVTN phase I clinical trial participants: Enrollment, risk reduction counseling and retention.I 期临床试验参与者的物质使用模式:入组、风险降低咨询和保留。
Vaccine. 2018 Feb 21;36(9):1235-1242. doi: 10.1016/j.vaccine.2017.11.032.

引用本文的文献

1
Profile of vaccine research: A bibliometric analysis.疫苗研究概况:一项文献计量分析
Hum Vaccin Immunother. 2025 Dec;21(1):2459459. doi: 10.1080/21645515.2025.2459459. Epub 2025 Feb 5.
2
Impact of National Institutes of Health and Food and Drug Administration Tobacco Research Funding: A Bibliometrics Analyses.美国国立卫生研究院和美国食品和药物管理局烟草研究经费的影响:文献计量学分析。
Nicotine Tob Res. 2023 May 22;25(6):1082-1089. doi: 10.1093/ntr/ntad024.
3
Global Research Trend in Vaccine Design.疫苗设计的全球研究趋势

本文引用的文献

1
HIV/AIDS research in Africa and the Middle East: participation and equity in North-South collaborations and relationships.非洲和中东的艾滋病毒/艾滋病研究:南北合作和关系中的参与和公平性。
Global Health. 2020 Sep 17;16(1):83. doi: 10.1186/s12992-020-00609-9.
2
Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans.泰国人和南非人中痘蛋白 HIV 疫苗结合抗体和 T 细胞反应的景观。
PLoS One. 2020 Jan 30;15(1):e0226803. doi: 10.1371/journal.pone.0226803. eCollection 2020.
3
Broadly Neutralizing Antibodies for HIV Prevention.
Vaccines (Basel). 2022 Nov 29;10(12):2034. doi: 10.3390/vaccines10122034.
4
Global representation of heart failure clinical trial leaders, collaborators, and enrolled participants: a bibliometric review 2000-20.全球心力衰竭临床试验领导者、合作者和入组参与者的代表性:2000-20 年的文献计量学回顾
Eur Heart J Qual Care Clin Outcomes. 2022 Sep 5;8(6):659-669. doi: 10.1093/ehjqcco/qcab058.
广谱中和抗体用于 HIV 预防。
Annu Rev Med. 2020 Jan 27;71:329-346. doi: 10.1146/annurev-med-110118-045506.
4
Prophylactic HIV vaccine: vaccine regimens in clinical trials and potential challenges.预防性 HIV 疫苗:临床试验中的疫苗方案及潜在挑战。
Expert Rev Vaccines. 2020 Feb;19(2):133-142. doi: 10.1080/14760584.2020.1718497. Epub 2020 Feb 20.
5
Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein.评价 HIV 亚型 C DNA 疫苗和 MF59 佐剂的 HIV 亚型 C 包膜蛋白的安全性和免疫原性的 1 期人体免疫缺陷病毒(HIV)疫苗试验。
Clin Infect Dis. 2021 Jan 23;72(1):50-60. doi: 10.1093/cid/ciz1239.
6
The complex challenges of HIV vaccine development require renewed and expanded global commitment.艾滋病病毒疫苗研发面临的复杂挑战需要全球做出新的、更广泛的承诺。
Lancet. 2020 Feb 1;395(10221):384-388. doi: 10.1016/S0140-6736(19)32682-0. Epub 2019 Dec 2.
7
Predicting translational progress in biomedical research.预测生物医学研究中的转化进展。
PLoS Biol. 2019 Oct 10;17(10):e3000416. doi: 10.1371/journal.pbio.3000416. eCollection 2019 Oct.
8
HIV Testing in 50 Local Jurisdictions Accounting for the Majority of New HIV Diagnoses and Seven States with Disproportionate Occurrence of HIV in Rural Areas, 2016-2017.2016-2017 年,50 个地方司法管辖区进行了艾滋病毒检测,这些地区占新诊断出的艾滋病毒病例的大多数,以及七个农村地区艾滋病毒发病率不成比例的州。
MMWR Morb Mortal Wkly Rep. 2019 Jun 28;68(25):561-567. doi: 10.15585/mmwr.mm6825a2.
9
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.C 亚型 ALVAC-HIV 和双价 C 亚型 gp120/MF59 HIV-1 疫苗在南非低危、未感染 HIV 的成年人中的 1/2 期临床试验
Lancet HIV. 2018 Jul;5(7):e366-e378. doi: 10.1016/S2352-3018(18)30071-7. Epub 2018 Jun 18.
10
An HIV Vaccine Is Essential for Ending the HIV/AIDS Pandemic.一种HIV疫苗对于终结HIV/AIDS大流行至关重要。
JAMA. 2017 Oct 24;318(16):1535-1536. doi: 10.1001/jama.2017.13505.